These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16368455)

  • 21. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection.
    Tsai MK; Chueh SC; Hu RH; Lee PH
    J Formos Med Assoc; 2003 Feb; 102(2):91-6. PubMed ID: 12709737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients.
    Lewis RL; Canafax DM; Pettit KG; DiCesare J; Kaniecki DJ; Arnold RJ; Roberts MS
    Transplant Proc; 1996 Aug; 28(4):2214-7. PubMed ID: 8769203
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Cost-effectiveness Analysis of Rabbit Antithymocyte Globulin Versus Antithymocyte Globulin-fresenius as Induction Therapy for Patients With Kidney Transplantation From Donation After Cardiac Death in China.
    Xuan D; Chen G; Wang C; Yao X; Yin H; Zhang L; Xuan J; Chen L
    Clin Ther; 2018 Oct; 40(10):1741-1751. PubMed ID: 30243768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients.
    Holmes M; Chilcott J; Walters S; Whitby S; Akehurst R
    Transpl Int; 2004 May; 17(4):182-7. PubMed ID: 15107971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two-hour post-dose cyclosporine levels in renal transplantation in Argentina: a cost-effective strategy for reducing acute rejection.
    Balshaw R; Machnicki G; Carreño CA; Toselli L; Otero A; Keown PA
    Transplant Proc; 2005 Mar; 37(2):871-4. PubMed ID: 15848560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective.
    Walters SJ; Whitfield M; Akehurst RL; Chilcott JB
    Pharmacoeconomics; 2003; 21(2):129-38. PubMed ID: 12515574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal transplantation.
    Gamboa O; Montero C; Mesa L; Benavides C; Reino A; Torres RE; Castillo JS
    Transplant Proc; 2011 Nov; 43(9):3367-76. PubMed ID: 22099798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database.
    Watt KD; Dierkhising R; Heimbach JK; Charlton MR
    Liver Transpl; 2012 Sep; 18(9):1029-36. PubMed ID: 22641474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sirolimus Versus Tacrolimus as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation.
    Liu JY; Song M; Guo M; Huang F; Ma BJ; Zhu L; Xu G; Li J; You RX
    Am J Ther; 2016; 23(6):e1720-e1728. PubMed ID: 25569597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost of kidney transplant over time.
    Barnieh L; Yilmaz S; McLaughlin K; Hemmelgarn BR; Klarenbach S; Manns BJ; For The Alberta Kidney Disease Network
    Prog Transplant; 2014 Sep; 24(3):257-62. PubMed ID: 25193726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients.
    Flechner SM; Gurkan A; Hartmann A; Legendre CM; Russ GR; Campistol JM; Schena FP; Hahn CM; Li H; Korth-Bradley JM; Tai SS; Schulman SL
    Transplantation; 2013 May; 95(10):1233-41. PubMed ID: 23689085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sirolimus versus calcineurin inhibitor-based immunosuppressive therapy in kidney transplantation: a 4-year follow-up.
    Nafar M; Alipour B; Ahmadpoor P; Pour-Reza-Gholi F; Samadian F; Samavat S; Farhangi S
    Iran J Kidney Dis; 2012 Jul; 6(4):300-6. PubMed ID: 22797101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sirolimus (rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: an initial experience in Taiwan.
    Liu KL; Chu SH; Chiang YJ; Wu CT; Chen Y
    Transplant Proc; 2004 Sep; 36(7):2051-2. PubMed ID: 15518742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steroid-free maintenance immunosuppression with rapamune and low-dose neoral in pancreas transplant recipients.
    Rajab A; Pelletier RP; Ferguson RM; Elkhammas EA; Bumgardner GL; Henry ML
    Transplantation; 2007 Nov; 84(9):1131-7. PubMed ID: 17998868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
    Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
    Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.